$3.65
-0.36 (-8.98%)
Open$4.04
Previous Close$4.01
Day High$4.04
Day Low$3.64
52W High$20.32
52W Low$0.72
Volume—
Avg Volume40.0K
Market Cap54.32M
P/E Ratio—
EPS$-1.69
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+725.8% upside
Current
$3.65
$3.65
Target
$30.14
$30.14
$22.58
$30.14 avg
$41.69
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.48M | 2.49M | 2.71M |
| Net Income | -380,025 | -467,867 | -467,071 |
| Profit Margin | -15.3% | -18.8% | -17.2% |
| EBITDA | -552,767 | -558,041 | -685,415 |
| Free Cash Flow | -221,579 | -328,689 | -323,480 |
| Rev Growth | +22.9% | +23.1% | -7.6% |
| Debt/Equity | 0.29 | 0.26 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |